AR and benign prostatic hyperplasia: The 5ARIs, such as finasteride (Fi), inhibit the conversion of testosterone to DHT because they inhibit 5α-reductase type2 (5AR2); consequently, they prevent AR binding and reduce PSA levels in BPH patients.